Business Wire

BIOGEN-IDEC

Del
Biogen Idec Announces Official Partnership with Sailing Sclerosis’ “Oceans of Hope” to Globally Change Perceptions of MS

In celebration of World MS Day and as part of its ongoing mission to support those living with Multiple Sclerosis ( MS) globally, Biogen Idec (NASDAQ: BIIB) announced that it has joined the Sailing Sclerosis Foundation’s (SSF) Oceans of Hope project as principal sponsor and official partner. This multi-year, global campaign is designed to use sailing as a means to educate and empower the MS community, changing perceptions of what it means to live with the disease and demonstrating the benefits of an active lifestyle.

The Oceans of Hope project was pioneered by Dr. Mikkel Anthonisen, Founder of SSF and a MS specialist at Copenhagen University Hospital, Rigshospitalet. He and several other crew members, including some living with MS, will sail around the world, building strong bonds with the global MS community.

“We are proud to be a part of the Oceans of Hope project, which fits perfectly with our more than three decade commitment to supporting the MS community through innovative science and patient programs,” said David Allsop, senior vice president, Europe and Canada for Biogen Idec. “Treatment of MS needs to be holistic – incorporating the right therapies with community programs and resources. Through its message of empowerment, we believe that Oceans of Hope can benefit thousands of patients around the world.”

The campaign will kick off today in Copenhagen, Denmark with the official naming of the boat. It will officially launch from Copenhagen on June 15, after which the boat will stop in multiple harbors in Europe, North America, South America, and Australia. Each port day will be celebrated with an interactive event, giving people living with MS the opportunity to learn to sail and participate as crew members.

"We are delighted to partner with Biogen Idec. Oceans of Hope aims to change perceptions of MS by showing what is possible when people with a chronic disease are empowered to conquer their individual challenges,” said Dr. Anthonisen. “As a physician, I see that each person who has MS is unique and needs access to different resources to treat their individual disease. The voyage will also carry this year's World MS Day theme of access across the globe, building stronger bonds across the global MS and sailing communities."

For more information about Oceans of Hope and SSF, where the boat will stop, or how to participate in the program, please visit: www.sailingsclerosis.com . The boat’s voyage can be followed via SSF social media either via Twitter @sailsclerosis, Facebook at www.facebook.com/OceansofHope , and Instagram at OceansofHope.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system, which is made up of the brain, spinal cord and optic nerves. Symptoms may be mild or severe, ranging from numbness in the limbs to paralysis or loss of vision. The progression, severity and specific symptoms of MS are unpredictable and vary from one person to another. MS affects more than 2.3 million people worldwide,1 with more than 500,000 sufferers in the European Union.2 Relapsing forms of MS include: relapsing-remitting MS (RRMS), the most common form of the disease accounting for 85 percent of cases, which is characterized by clearly defined acute attacks with full recovery or with residual deficit upon recovery;3 and progressive-relapsing MS, which affects 5 percent of people with MS and is characterized by steadily worsening disease from the beginning with occasional acute attacks like those experienced by people with RRMS.4

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies. For product labeling, press releases and additional information about the Company, please visit www.biogenidec.com .

Biogen Idec is also on Twitter (@biogenidec): www.twitter.com/biogenidec

References

1 Multiple Sclerosis International Federation, Atlas of MS 2013. Epidemiology of MS . Page 8. Date Accessed: Mar. 17, 2014. http://www.msif.org/includes/documents/cm_docs/2013/m/msif-atlas-of-ms-2013-report.pdf?f=1

2 Multiple Sclerosis International Federation. Atlas of MS 2013. Epidemiology of MS . Date Accessed: Mar. 17, 2014. http://www.atlasofms.org/query.aspx

3 NMSS. Relapsing-Remitting MS . Date accessed: Mar. 17, 2014. http://www.nationalmssociety.org/What-is-MS/Types-of-MS/Relapsing-remitting-MS

4 NMSS. Progressive-Relapsing MS. Date accessed: March 17, 2014. http://www.nationalmssociety.org/What-is-MS/Types-of-MS/Progressive-relapsing-MS

Contact:

Biogen Idec International
Shannon Altimari, +41 41 392 16 77
publicaffairs.EU@biogenidec.com

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

FES Super Extends Partnership with SS&C28.5.2025 00:13:00 CEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the Fire and Emergency Services Superannuation Fund (“FES Super”) has signed a long-term agreement to extend its existing partnership with SS&C. The renewal reinforces SS&C’s leadership and continued growth in the Australian superannuation market, following several recent strategic wins in the region. FES Super leverages SS&C Bluedoor, a cloud-hosted registry platform, to manage its administration needs. The platform enables real-time automation and straight-through processing, helping streamline operations and improving member experiences. SS&C also provides member digital and reporting services to the fund. “Our top priority is acting in the best interests of our members,” said Adrian Rutter, Fund Secretary at FES Super. “SS&C’s flexible, customizable tools and consistent service enable us to continue doing just that. By leveraging Bluedoor’s integration capabilities and cloud-native services, we can efficiently deliver

Perma-Pipe International Holdings, Inc. Announces New Contract Award in Qatar27.5.2025 21:48:00 CEST | Press release

Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced that it has received its first project award to be executed in Qatar since the announcement of the intent to mobilize there. The project will be for USD $2.4 million and will utilize Perma-Pipe’s fabrication capabilities and the XTRU-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Adham Sharkawy, Senior Vice President of Perma-Pipe’s MENA region, remarked, “In response to this important award, we will begin executing the project from a temporary facility in Doha, ensuring timely delivery and uninterrupted service to our client. Simultaneously, we are advancing the construction of our permanent facility in Qatar, which will serve as a long-term base for our regional operations. We are deeply grateful to our customers for their continued trust and confidence in Perma-Pipe’s capabilities.” Saleh Sagr, President, commented, “Expanding in Doha has been an impo

Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 17:46:00 CEST | Press release

Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de

New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 17:44:00 CEST | Press release

Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,

LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 17:00:00 CEST | Press release

~New server connects AI assistants directly to test execution data, streamlining debugging and accelerating development~ LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances aut

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye